A regulatory requirement non-interventional study to monitor the safety and effectiveness of Spesolimab in Korean patients with flares with generalized pustular psoriasis

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/1000000278
• EU PAS number:
  EUPAS1000000278
• Study ID:
  1000000278
• Official title and acronym:
  A regulatory requirement non-interventional study to monitor the safety and effectiveness of Spesolimab in Korean patients with flares with generalized pustular psoriasis
• DARWIN EU® study:
  No
• Study countries:
  Korea, Republic of
• Study status:
  Planned

Study timelines

Date when funding contract was signed

Planned: 09/08/2023

Actual: 09/08/2023

Study start date

Planned: 30/03/2026

Date of final study report

Planned: 31/05/2029

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  Non-EU RMP only